"Interesting questions posed in the reply were, "If someone is doing this professionally, then who is doing it? More importantly, WHY are they doing it? We are a small company with great technology and expanding sales and someone has shown they are determined to ignore what we have and focus on hurting the share price. Someone has a reason for trading small amounts of shares in clearly definable patterns to damage us."
Message from poster Emerald Isle on I-Hub claiming a recent e-mail response from the company.
Hey, maybe Parents had to settle up on that home equity loan?
"Antibiotic Effectiveness in Space-1(AES-1) evaluates the effectiveness of antibiotics against bacteria grown in the space flight environment. Group Activation Packs (GAPs) containing eight Fluids Processing Apparatuses (FPAs) are used to process the bacterial samples. Specifically, once on orbit, the GAP hardware is operated so as to inoculate nutrient rich media with Escherichia coli (E. coli) bacterial cultures. When the bacteria are undergoing exponential growth, various concentrations of known antibiotics including Gentamicin Sulfate and Colistin Sulfate are introduced. After being exposed to the antibiotics for approximately 12-24 hours, half of the samples are preserved by introducing RNAlater® II (a preservative) into the cultures and half of the samples are fixed by introducing paraformaldehyde (fixative). Bacteria in space that are still able to grow at what would be normally inhibitory concentrations of the antibiotic on the ground are brought back to Earth and assessed for alterations in gene expression and changes in shape and structure that might explain their ability to survive in the space flight environment. This work may lead to a greater understanding of antibiotic efficacy and more effective treatment of infectious disease world-wide."
A little experiment just done last month at the ISS.....a Group Activation Pack inoculating nutrient rich media?
"Momentum continues to build across our business, with strong execution on our test menu, geographic expansion, and market extension programs all contributing to record first quarter revenue," said John Bishop, Cepheid's Chairman and Chief Executive Officer. "In the last 12 months, Cepheid has added eight tests to the international Xpert menu, including the milestone HIV Viral Load, HIV Qualitative and HCV Viral Load tests. Regardless of size, many of our international customers now have the capability to offer a broad molecular menu of HAI, critical infectious disease, sexual health and virology tests on a single accurate, efficient, scalable, and cost-effective platform."
Somebody likes CPHD...stock up $6/share today. Good 1st qtr numbers....revenue 24% above 1st qtr 2014.
Robert-A. Ollar, Ph.d
Sr. Scientist, Research & Development at NanoLogix
"He is a member of the WHO Global Stop TB Partnership and also serves as a Foreign Advisor for Mycobacterial and Nocardial Diseases at the Mahatma Gandhi Institute of Medical Sciences in Sevagram India."
This appears to me as a very well connected fellow at the WHO and in India."
Remember when the home gamers were pumping this guy's connections? He's now a member of the Pennsylvania Tick & Lyme Disease Task Force.
Can't give Barnhizer high marks for staff development & retention.